223785-85-1

Basic information

• Product Name: 2-Bromo-2'-fluoro-6'-(trifluoromethyl)acetophenone, 2-Bromo-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethan-1-one
• Synonyms: 2-Bromo-2'-fluoro-6'-(trifluoromethyl)acetophenone, 2-Bromo-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethan-1-one;2-Fluoro-6-(trifluoromethyl)phenacyl bromide 97%;2-Fluoro-6-(trifluoromethyl)phenacylbromide97%
• CAS NO: 223785-85-1
• Molecular Formula: C₉H₅BrF₄O
• Molecular Weight: 285.0330128
• Mol File: 223785-85-1.mol

Chemical Properties

• Boiling Point: 252.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.658±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-Bromo-2'-fluoro-6'-(trifluoromethyl)acetophenone, 2-Bromo-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-2'-fluoro-6'-(trifluoromethyl)acetophenone, 2-Bromo-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethan-1-one(223785-85-1)
• EPA Substance Registry System: 2-Bromo-2'-fluoro-6'-(trifluoromethyl)acetophenone, 2-Bromo-1-[2-fluoro-6-(trifluoromethyl)phenyl]ethan-1-one(223785-85-1)

Safety Data

• Hazardous Substances Data: 223785-85-1(Hazardous Substances Data)

Upstream product

• 174013-29-7 2'-fluoro-6'-(trifluoro-methyl)acetophenone 

Relevant articles and documents

AROMATIC HETEROCYCLIC COMPOUND

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

A new approach to the synthesis of 2-aminoimidazo[1,2-a]pyridine derivatives through rapid parallel synthesis

Different substituted 6-(2,6-difluorobenzoyl)-imidazopyridines 3 have been prepared using rapid parallel synthesis. Key cyanamide intermediate 4 was prepared from chloropyridine 1, and alkylated at the endocyclic nitrogen with different bromoacetophenones (prepared also in rapid parallel synthesis fashion). Subsequent cyclization was performed in situ with EtOAc/H2O to give target molecules.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.